Recombinant adeno-associated virus-based gene therapy combined with tissue engineering for musculoskeletal regenerative medicine.
Level 5 - mechanism / opinion, no new human data
Narrative review of rAAV gene delivery and biomaterial strategies with no original human clinical data or systematic synthesis
PubMed 35837257 · doi:10.3877/cma.j.issn.2096-112X.2021.01.004
What was done
This narrative review summarizes progress, biomaterial scaffolds, and delivery architectures used in combinatorial strategies combining recombinant adeno-associated viral (rAAV) vector-mediated gene delivery with tissue engineering approaches for musculoskeletal regenerative medicine.
What was found
The abstract reports no quantitative data or specific numerical outcomes. It qualitatively describes how incorporating rAAV vectors into biomaterial scaffolds can enhance controlled transgene expression, reduce host immune responses, and improve transduction efficiency compared to standard vector delivery, while acknowledging that different biomaterial designs carry distinct advantages and limitations.
Why it matters
rAAV delivery alone faces challenges including rapid vector degradation and suboptimal transduction efficiency in musculoskeletal tissues. Integrating viral gene therapy with tissue engineering scaffolds provides a structural and biological platform aimed at improving targeted tissue regeneration.
Limits
The abstract provides no quantitative metrics, specific comparative trial results, or sample sizes. As a narrative review, it lacks systematic search methodology, risk-of-bias assessment, and standardized evaluation of clinical translation feasibility.
Cited by
- supports Introducing genes into cells using viral vectors or plasmids can cause engineered tissues to express foreign antigens that trigger immune rejection upon transplantation.